China Clears First Coronavirus Vaccine Trial
Leveraging its Ebola vaccine success, Tianjin-based CanSino is looking to launch China’s first vaccine for COVID-19 as it secures permission to start local clinical trials.
You may also be interested in...
Ke Wu, CEO of Wuhan-based BravoVax, tells Scrip in an exclusive interview why front-runner vaccines for coronavirus that enter clinical studies may not necessarily be successful, and why small innovative Chinese firms may be best positioned to seize opportunities as the government rallies both internal and external support for the development effort.
As China is poised to supply globally medical products to fight coronavirus, a battle to banish its image of poor product quality is on.
China insurance giant snatches up stakes in Japanese pharma and a traditional Chinese medicines maker with a $465m spending spree.